CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,861 enrolled
Drug / intervention
Standard inactivated influenza vaccine (NH formulation) +3 morebiological
Likely dose
Standard inactivated influenza vaccine (NH formulation) 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03330132
NCT03330132Phase 4Completed
CompareCT.gov

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial

The University of Hong Kong·interventional·Posted Nov 6, 2017·Updated May 15, 2026

In Brief

A Phase 4 clinical trial evaluating Standard inactivated influenza vaccine (NH formulation), MF 59 adjuvanted inactivated influenza vaccine (NH formulation), and 2 other interventions for Influenza, Human. Completed, enrolled 1,861 participants across 1 site.

Detailed Summary

This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human
CountriesChina
CollaboratorsCenters for Disease Control and Prevention

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedNov 6, 2017
Enrollment StartOct 7, 2017
Primary CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 8.7 years ago

Interventions

Standard inactivated influenza vaccine (NH formulation)biological

0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.

MF 59 adjuvanted inactivated influenza vaccine (NH formulation)biological

0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

High-dose inactivated influenza vaccine (NH formulation)biological

0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)biological

0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.